Jasper Therapeutics (JSPR) is presenting updated clinical data from the Phase 1b/2a BEACON study, as well as data from four preclinical studies evaluating briquilimab, at the AAAAI 2025 Annual ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback